The neuropathology of Parkinson’s disease dementia (PDD) is heterogenous, and the impacts of each pathophysiology and their synergistic effects are not fully understood. The aim of this study was to evaluate the frequency and impacts of co-existence with Alzheimer’s disease in patients with PDD by using 18F-florbetaben PET imaging. A total of 23 patients with PDD participated in the study. All participants underwent 18F-florbetaben PET and completed a standardized neuropsychological battery and assessment of motor symptoms. The results of cognitive tests, neuropsychiatric symptoms, and motor symptoms were analyzed between the positive and negative 18F-florbetaben PET groups. Four patients (17.4%) showed significant amyloid burden. Patients with amyloid-beta showed poorer performance in executive function and more severe neuropsychiatric symptoms than those without amyloid-beta. Motor symptoms assessed by UPDRS part III and the modified H&Y Scale were not different between the two groups. The amyloid PET scan of a patient with PDD can effectively reflect a co-existing Alzheimer’s disease pathology. Amyloid PET scans might be able to help physicians of PDD patients showing rapid progression or severe cognitive/behavioral features.

中文翻译：

---

淀粉样蛋白正阳性与18F-氟倍他本PET对帕金森氏病痴呆症的神经心理学方面的影响

帕金森氏病痴呆症（PDD）的神经病理学是异质的，并且每种病理生理学的影响及其协同作用尚不完全清楚。这项研究的目的是通过18F-florbetabenben PET成像评估PDD患者与阿尔茨海默氏病共存的频率和影响。共有23名PDD患者参加了该研究。所有参与者都接受了18F-florbetaben PET的治疗，并完成了标准化的神经心理训练和运动症状评估。分析阳性和阴性18F-florbetaben PET组之间的认知测验，神经精神症状和运动症状的结果。四名患者（17.4％）显示出明显的淀粉样蛋白负担。与没有淀粉样蛋白β的患者相比，具有淀粉样蛋白β的患者表现出较差的执行功能和更严重的神经精神症状。两组之间通过UPDRS第三部分和改良的H＆Y量表评估的运动症状无差异。PDD患者的淀粉样蛋白PET扫描可以有效反映并存的阿尔茨海默氏病病理。淀粉样蛋白PET扫描可能会帮助PDD患者的医师显示出快速进展或严重的认知/行为特征。